NPI: 1053375576 · OXFORD, MS 38655 · General Acute Care Hospital · NPI assigned 04/13/2006
Authorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
| Authorized Official | DUCKETT, GREGORY (SR VP/CLO) |
| Parent Organization | BAPTIST MEMORIAL HEALTH CARE CORP. |
| NPI Enumeration Date | 04/13/2006 |
Other providers sharing the same authorized official: DUCKETT, GREGORY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 182,403 | $6.23M |
| 2019 | 196,799 | $5.85M |
| 2020 | 158,414 | $5.36M |
| 2021 | 165,450 | $5.32M |
| 2022 | 170,037 | $5.12M |
| 2023 | 167,334 | $6.03M |
| 2024 | 124,925 | $5.03M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 28,272 | 23,017 | $5.16M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 23,918 | 20,131 | $3.29M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16,676 | 13,600 | $3.24M |
| G0378 | Hospital observation service, per hour | 8,246 | 5,229 | $2.49M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 17,175 | 13,426 | $1.28M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3,405 | 2,973 | $1.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6,982 | 5,637 | $1.04M |
| J9271 | Injection, pembrolizumab, 1 mg | 288 | 160 | $836K |
| D2930 | Prefabricated stainless steel crown - primary tooth | 16,136 | 2,237 | $808K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7,278 | 3,041 | $805K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9,068 | 7,971 | $789K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2,292 | 1,962 | $746K |
| 71045 | Radiologic examination, chest; single view | 20,623 | 16,256 | $690K |
| D0272 | Bitewings - two radiographic images | 961 | 829 | $687K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4,573 | 3,934 | $663K |
| 96361 | Intravenous infusion, hydration; each additional hour | 11,723 | 7,425 | $625K |
| D7140 | Extraction, erupted tooth or exposed root | 1,809 | 454 | $618K |
| J2505 | Injection, pegfilgrastim, 6 mg | 527 | 282 | $613K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 7,133 | 4,092 | $551K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 19,221 | 12,118 | $514K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 6,002 | 4,611 | $429K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1,430 | 1,092 | $421K |
| J0897 | Injection, denosumab, 1 mg | 1,026 | 613 | $409K |
| 93458 | 550 | 441 | $407K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 18,178 | 11,320 | $394K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 22,591 | 16,126 | $387K |
| 80053 | Comprehensive metabolic panel | 53,548 | 38,527 | $341K |
| 71046 | Radiologic examination, chest; 2 views | 7,943 | 6,787 | $338K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 7,274 | 6,284 | $338K |
| 70450 | Computed tomography, head or brain; without contrast material | 7,724 | 6,222 | $328K |
| D2934 | 4,850 | 1,093 | $320K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 64,021 | 42,666 | $268K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6,280 | 1,673 | $259K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 9,377 | 7,057 | $256K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9,345 | 7,718 | $246K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 9,108 | 2,027 | $241K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 19,445 | 8,471 | $232K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,603 | 2,172 | $226K |
| D3330 | Endodontic therapy, molar tooth (excluding final restoration) | 1,336 | 330 | $224K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2,801 | 2,256 | $222K |
| 36415 | Collection of venous blood by venipuncture | 78,896 | 51,418 | $177K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2,611 | 2,107 | $172K |
| 93017 | 2,544 | 2,171 | $167K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12,689 | 10,044 | $165K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2,118 | 1,742 | $154K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2,736 | 2,383 | $152K |
| 86900 | 3,641 | 2,761 | $151K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 4,341 | 1,043 | $146K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1,552 | 1,290 | $135K |
| D3320 | 384 | 170 | $128K | |
| D3310 | 972 | 243 | $127K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3,185 | 2,617 | $127K |
| 83880 | 6,426 | 5,074 | $125K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 3,164 | 1,687 | $125K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 649 | 569 | $122K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1,242 | 647 | $121K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6,157 | 1,074 | $119K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 747 | 608 | $117K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4,123 | 3,260 | $114K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 2,126 | 862 | $113K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,356 | 2,986 | $106K |
| 84484 | 17,793 | 9,868 | $106K | |
| 73560 | 2,765 | 2,267 | $97K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 14,387 | 7,487 | $88K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 440 | 203 | $84K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,892 | 2,483 | $74K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1,126 | 827 | $73K |
| 81001 | 29,244 | 22,864 | $70K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 2,018 | 1,580 | $69K |
| 73630 | 1,782 | 1,500 | $68K | |
| 86901 | 4,542 | 3,489 | $63K | |
| 73610 | 1,456 | 1,207 | $61K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 12,128 | 8,768 | $60K |
| 86850 | 3,080 | 2,307 | $56K | |
| 73130 | 1,393 | 1,149 | $56K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8,239 | 6,924 | $54K |
| 93971 | 1,435 | 1,253 | $53K | |
| 84443 | Thyroid stimulating hormone (TSH) | 5,440 | 4,304 | $52K |
| 83735 | 14,487 | 10,181 | $51K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 798 | 711 | $51K |
| 85027 | 13,411 | 9,694 | $47K | |
| 73030 | 1,479 | 1,223 | $46K | |
| 72100 | 931 | 759 | $44K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2,893 | 2,588 | $42K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,008 | 1,376 | $42K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 8,241 | 6,796 | $42K |
| 77336 | 850 | 255 | $42K | |
| 76000 | 411 | 320 | $40K | |
| D1120 | Prophylaxis - child | 3,042 | 2,408 | $39K |
| 81025 | 6,403 | 5,106 | $38K | |
| 73502 | 1,339 | 1,034 | $38K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2,389 | 1,840 | $38K |
| 87040 | 8,139 | 3,702 | $38K | |
| 96367 | 1,666 | 979 | $37K | |
| 83690 | 8,585 | 6,854 | $36K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 584 | 462 | $35K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 514 | 221 | $34K |
| 70486 | 470 | 389 | $34K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,442 | 1,210 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,442 | 1,210 | $33K |
| 84702 | 3,083 | 2,100 | $32K | |
| 41899 | Unlisted procedure, dentoalveolar structures | 201 | 182 | $31K |
| 72131 | 902 | 722 | $30K | |
| 97162 | 1,016 | 830 | $30K | |
| 83605 | 6,192 | 4,457 | $29K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 296 | 263 | $29K |
| J0185 | Injection, aprepitant, 1 mg | 361 | 145 | $28K |
| D1208 | Topical application of fluoride, excluding varnish | 3,041 | 2,411 | $28K |
| 74018 | 589 | 483 | $28K | |
| 96417 | 1,182 | 508 | $27K | |
| 96415 | 619 | 385 | $25K | |
| 84703 | 5,216 | 4,270 | $25K | |
| 87807 | 2,283 | 2,036 | $25K | |
| 85610 | 11,577 | 8,680 | $25K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 168 | 140 | $24K |
| 36430 | 252 | 167 | $23K | |
| 85730 | 7,026 | 5,600 | $22K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 282 | 272 | $22K |
| 76801 | 311 | 266 | $22K | |
| 80061 | Lipid panel | 2,864 | 2,324 | $22K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1,325 | 330 | $22K |
| 97602 | 296 | 160 | $18K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 351 | 306 | $18K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 55 | 53 | $17K |
| 36600 | 612 | 505 | $16K | |
| 71250 | 377 | 324 | $15K | |
| 73590 | 396 | 341 | $15K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 50 | 29 | $15K |
| 86160 | 2,371 | 911 | $15K | |
| 86923 | 438 | 177 | $14K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 830 | 730 | $14K |
| P9016 | Red blood cells, leukocytes reduced, each unit | 209 | 127 | $14K |
| 82728 | 1,995 | 1,480 | $13K | |
| Q3014 | Telehealth originating site facility fee | 2,109 | 1,270 | $13K |
| 86140 | 4,493 | 3,546 | $13K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | 677 | 139 | $13K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 657 | 536 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2,318 | 1,897 | $12K |
| 85379 | 1,952 | 1,651 | $12K | |
| 96411 | 579 | 210 | $12K | |
| 82803 | 754 | 605 | $11K | |
| 96416 | 105 | 38 | $10K | |
| 97533 | 217 | 112 | $10K | |
| 74019 | 143 | 130 | $10K | |
| 82378 | 1,448 | 797 | $10K | |
| 74022 | 163 | 127 | $10K | |
| 82607 | 1,398 | 978 | $9K | |
| 85007 | 3,677 | 2,899 | $9K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 565 | 221 | $9K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 412 | 89 | $8K |
| 97166 | 245 | 210 | $8K | |
| 72170 | 177 | 136 | $8K | |
| C9463 | Injection, aprepitant, 1 mg | 48 | 27 | $8K |
| 74178 | 61 | 49 | $8K | |
| 82565 | 2,474 | 2,087 | $7K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 37 | 37 | $7K |
| 87070 | 1,343 | 1,029 | $7K | |
| 83550 | 1,764 | 1,290 | $7K | |
| 73090 | 171 | 140 | $6K | |
| 85652 | 4,186 | 3,311 | $6K | |
| 94726 | 90 | 82 | $6K | |
| 80074 | 214 | 165 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 80 | 67 | $6K |
| 82375 | 705 | 568 | $6K | |
| 99215 | Prolong outpt/office vis | 181 | 145 | $6K |
| 96377 | 557 | 274 | $5K | |
| 83540 | 1,856 | 1,366 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | 9,644 | 3,950 | $5K |
| A9270 | Non-covered item or service | 12,348 | 5,783 | $5K |
| 86038 | 651 | 500 | $4K | |
| 84439 | 823 | 634 | $4K | |
| 82570 | 1,506 | 1,142 | $4K | |
| 92523 | 31 | 25 | $4K | |
| 87205 | 1,632 | 1,136 | $4K | |
| 73070 | 111 | 100 | $4K | |
| 73100 | 96 | 76 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 23 | 19 | $4K |
| 85014 | 2,542 | 1,939 | $4K | |
| 86003 | 1,451 | 67 | $4K | |
| 84132 | 1,401 | 1,106 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 157 | 121 | $3K |
| 82550 | 961 | 735 | $3K | |
| 77334 | 23 | 12 | $3K | |
| J1453 | Injection, fosaprepitant, 1 mg | 24 | 12 | $3K |
| 84156 | 1,644 | 1,184 | $3K | |
| 86300 | 552 | 258 | $3K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1,518 | 1,135 | $3K |
| 83050 | 693 | 563 | $3K | |
| 97597 | 54 | 37 | $3K | |
| 72128 | 118 | 80 | $3K | |
| 82746 | 659 | 470 | $3K | |
| 87797 | 154 | 137 | $3K | |
| 83883 | 934 | 270 | $3K | |
| 87480 | 123 | 111 | $3K | |
| 77065 | Tomosynthesis, mammo | 51 | 48 | $3K |
| 70496 | 54 | 40 | $3K | |
| 85045 | 1,316 | 865 | $3K | |
| 88342 | 30 | 26 | $3K | |
| 72141 | 27 | 24 | $2K | |
| 73552 | 75 | 65 | $2K | |
| 87510 | 173 | 152 | $2K | |
| 43235 | 15 | 14 | $2K | |
| 83615 | 806 | 544 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 19,543 | 13,906 | $2K |
| 70498 | 53 | 39 | $2K | |
| 83516 | 323 | 151 | $2K | |
| 86235 | 283 | 50 | $2K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 187 | 53 | $2K |
| 84165 | 821 | 476 | $2K | |
| 84550 | 732 | 533 | $2K | |
| 85018 | 1,066 | 843 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 32 | 25 | $2K |
| 84100 | 669 | 466 | $2K | |
| J9045 | Injection, carboplatin, 50 mg | 188 | 87 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 24,596 | 16,577 | $1K |
| 80069 | 349 | 275 | $1K | |
| J9190 | Injection, fluorouracil, 500 mg | 555 | 104 | $1K |
| 72110 | 41 | 40 | $1K | |
| 92526 | 29 | 12 | $1K | |
| 97116 | 83 | 48 | $1K | |
| 73060 | 50 | 38 | $1K | |
| 96376 | 4,852 | 2,435 | $1K | |
| 10060 | 14 | 13 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 15,062 | 10,485 | $1K |
| 76641 | 24 | 14 | $1K | |
| 86431 | 339 | 259 | $1K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 69 | 15 | $976.32 |
| 96523 | 44 | 25 | $945.62 | |
| 76830 | Ultrasound, transvaginal | 15 | 12 | $882.58 |
| D2330 | 99 | 24 | $877.94 | |
| 71271 | 15 | 13 | $876.28 | |
| D0220 | Intraoral - periapical first radiographic image | 944 | 820 | $869.84 |
| 76536 | 13 | 12 | $857.10 | |
| 97163 | 31 | 25 | $823.72 | |
| 97161 | 44 | 39 | $813.66 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 57 | 41 | $787.20 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,971 | 12,012 | $786.74 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 846 | 646 | $759.09 |
| 75635 | 14 | 13 | $744.16 | |
| 72050 | 17 | 12 | $720.83 | |
| 86480 | 44 | 26 | $695.53 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 3,911 | 2,379 | $694.42 |
| 87493 | 26 | 26 | $682.58 | |
| D0230 | Intraoral - periapical each additional radiographic image | 690 | 605 | $664.97 |
| 0012A | 25 | 25 | $661.43 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 5,842 | 3,287 | $650.21 |
| 71101 | 14 | 12 | $600.82 | |
| 93880 | 15 | 14 | $600.43 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 1,660 | 1,162 | $576.30 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 2,339 | 1,942 | $522.39 |
| 82140 | 98 | 74 | $513.17 | |
| 74230 | 18 | 14 | $464.86 | |
| 86200 | 100 | 71 | $457.59 | |
| 87340 | 118 | 90 | $455.50 | |
| 72040 | 13 | 13 | $443.24 | |
| 0011A | 25 | 25 | $414.86 | |
| 82784 | 138 | 24 | $360.70 | |
| 90686 | 77 | 62 | $359.82 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 2,387 | 1,971 | $349.75 |
| 86225 | 55 | 43 | $348.93 | |
| 94760 | 2,992 | 1,713 | $337.72 | |
| 99442 | 14 | 14 | $328.75 | |
| C1769 | Guide wire | 2,835 | 2,114 | $319.01 |
| 80164 | 29 | 25 | $296.56 | |
| 88304 | 13 | 12 | $272.23 | |
| 99443 | 54 | 46 | $253.88 | |
| J2785 | Injection, regadenoson, 0.1 mg | 2,148 | 1,850 | $237.02 |
| 84155 | 195 | 144 | $222.86 | |
| 82785 | 17 | 13 | $202.62 | |
| J9267 | Injection, paclitaxel, 1 mg | 41 | 12 | $174.26 |
| 92611 | 18 | 14 | $148.50 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 7,916 | 5,577 | $143.41 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 11,851 | 9,175 | $133.11 |
| 96402 | 23 | 12 | $133.03 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 7,469 | 5,917 | $118.56 |
| D1206 | Topical application of fluoride varnish | 34 | 28 | $112.74 |
| 86780 | 13 | 12 | $95.72 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 181 | 75 | $90.70 |
| C9113 | Injection, pantoprazole sodium, per vial | 1,204 | 679 | $90.13 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 8,193 | 5,789 | $88.09 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 203 | 157 | $67.33 |
| 86334 | 15 | 13 | $67.05 | |
| 86308 | 13 | 12 | $66.81 | |
| J2704 | Injection, propofol, 10 mg | 13,234 | 9,809 | $63.15 |
| 99201 | 27 | 12 | $58.98 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 3,972 | 2,939 | $49.10 |
| 86706 | 13 | 12 | $48.55 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 360 | 146 | $46.88 |
| 82248 | 17 | 12 | $45.71 | |
| 36416 | 471 | 401 | $43.05 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 1,853 | 1,471 | $41.46 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 670 | 559 | $41.42 |
| J1170 | Injection, hydromorphone, up to 4 mg | 5,628 | 3,634 | $40.26 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 7,162 | 4,728 | $37.27 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 5,215 | 3,044 | $31.10 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 1,468 | 1,142 | $27.69 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 8,192 | 6,006 | $27.39 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 2,047 | 1,539 | $27.13 |
| 36592 | 40 | 27 | $20.72 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 4,899 | 2,056 | $20.24 |
| J3480 | Injection, potassium chloride, per 2 meq | 146 | 100 | $19.77 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 233 | 157 | $16.67 |
| 84145 | 4,026 | 3,128 | $14.29 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 38 | 25 | $10.47 |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 96 | 82 | $7.89 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 2,815 | 2,293 | $7.09 |
| J2060 | Injection, lorazepam, 2 mg | 287 | 205 | $6.50 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 1,426 | 995 | $5.85 |
| J1940 | Injection, furosemide, up to 20 mg | 758 | 413 | $1.92 |
| G0008 | Administration of influenza virus vaccine | 62 | 51 | $1.29 |
| 96368 | 318 | 115 | $1.28 | |
| J1644 | Injection, heparin sodium, per 1000 units | 3,175 | 1,697 | $0.54 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 441 | 329 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 112 | 67 | $0.00 |
| 94729 | 89 | 82 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 37 | 27 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 172 | 156 | $0.00 |
| 93356 | 178 | 168 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 221 | 165 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 188 | 168 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 89 | 70 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 214 | 160 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 33 | 26 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 64 | 60 | $0.00 |
| 77012 | 62 | 52 | $0.00 | |
| 76942 | 163 | 103 | $0.00 | |
| 90715 | 29 | 27 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 130 | 112 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 34 | 27 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 33 | 26 | $0.00 |
| C1776 | Joint device (implantable) | 19 | 12 | $0.00 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 44 | 19 | $0.00 |
| 76937 | 22 | 14 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 1,881 | 1,464 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 534 | 406 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 1,018 | 772 | $0.00 |
| J3490 | Unclassified drugs | 603 | 457 | $0.00 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | 896 | 320 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 758 | 581 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 1,787 | 1,378 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 1,646 | 1,341 | $0.00 |
| 80050 | General health panel | 102 | 91 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 484 | 388 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 159 | 113 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 52 | 52 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 205 | 75 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 607 | 151 | $0.00 |
| C1781 | Mesh (implantable) | 42 | 37 | $0.00 |
| 0352U | 178 | 137 | $0.00 | |
| 80349 | 29 | 24 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 18 | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 48 | 30 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 18 | 14 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 16 | 13 | $0.00 |